Literature DB >> 16231757

The Japanese Trial to Assess Optimal Systolic Blood Pressure in Elderly Hypertensive Patients (JATOS): protocol, patient characteristics, and blood pressure during the first 12 months.

.   

Abstract

The benefits of a systolic blood pressure (BP) below 150-160 mmHg are well established; whether a systolic BP of less than 140 mmHg provides additional benefits remains controversial. This study was designed to compare the 2-year effect of a strict treatment to maintain systolic BP below 140 mmHg (group A) and that of a mild treatment to maintain systolic BP at between 140 and below 160 mmHg (group B). The study design followed the Prospective Randomized Open Blinded End-point (PROBE) study. The subjects were elderly patients (65-85 years old) who consistently had a systolic BP of 160 mmHg or higher. The baseline drug was efonidipine hydrochloride (efonidipine), a long-acting dihydropiridine calcium antagonist. The primary endpoints were stroke, cardiac disease, vascular disease, and renal failure. After a run-in period of 2 to 4 weeks, 2,165 patients were assigned to group A and 2,155 patients to group B. There were no significant differences between the groups in sex, age, baseline BP, or other cardiovascular risk factors. The systolic BP was 7.2 mmHg lower (p < 0.0001) and the diastolic BP 2.4 mmHg lower (p < 0.0001) in group A than in group B after 12 months of treatment. As of this interim analysis, primary endpoints have occurred in 87 patients (stroke in 58 patients, cardiac disease in 27 patients, occlusive arterial disease in 1 patient, and renal failure in 1 patient). Five patients have died of stroke and 2 patients of myocardial infarction. The primary-endpoint-related morbidity rate was 20.9/1,000 patient-years, and the mortality rate was 1.7/1,000 patient-years. Currently available results indicate that this study, one of the largest randomized trials of antihypertensive therapy in elderly patients in Japan, was conducted safely. The final results are expected to provide important and practical information for the management of hypertension in elderly patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16231757     DOI: 10.1291/hypres.28.513

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  6 in total

Review 1.  Development of newer calcium channel antagonists: therapeutic potential of efonidipine in preventing electrical remodelling during atrial fibrillation.

Authors:  Narutaka Ohashi; Hideo Mitamura; Satoshi Ogawa
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 2.  Methods of Blood Pressure Assessment Used in Milestone Hypertension Trials.

Authors:  Yi Chen; Lei Lei; Ji-Guang Wang
Journal:  Pulse (Basel)       Date:  2018-07-18

3.  New Generation Calcium Channel Blockers in Hypertensive Treatment.

Authors:  Yuri Ozawa; Koichi Hayashi; Hiroyuki Kobori
Journal:  Curr Hypertens Rev       Date:  2006-05-01

4.  Effects of amlodipine and candesartan on arterial stiffness estimated by cardio-ankle vascular index in patients with essential hypertension: A 24-week study.

Authors:  Mie Kurata; Takafumi Okura; Sanae Watanabe; Jun Irita; Daijiro Enomoto; Masanori Johtoku; Ken-Ichi Miyoshi; Mitsuko Koresawa; Tomikazu Fukuoka; Jitsuo Higaki
Journal:  Curr Ther Res Clin Exp       Date:  2008-10

Review 5.  Isolated systolic hypertension in Asia.

Authors:  Tsung-Ying Tsai; Hao-Min Cheng; Shao-Yuan Chuang; Yook-Chin Chia; Arieska Ann Soenarta; Huynh Van Minh; Saulat Siddique; Yuda Turana; Jam Chin Tay; Kazuomi Kario; Chen-Huan Chen
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-11-29       Impact factor: 3.738

6.  Chronic Kidney Disease Progression Risk in Patients With Diabetes Mellitus Using Dihydropyridine Calcium Channel Blockers: A Nationwide, Population-Based, Propensity Score Matching Cohort Study.

Authors:  Shih-Yi Lin; Cheng-Li Lin; Cheng-Chieh Lin; Wu-Huei Hsu; Chung-Y Hsu; Chia-Hung Kao
Journal:  Front Pharmacol       Date:  2022-03-09       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.